Securities and Exchange Commission
Letters, Testimony & Comments
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.
September 29 2009
BIO supports NASDAQ’s proposal to temporarily suspend delisting standards during the economic crisis
April 20 2009
The Biotechnology Industry Organization (BIO) is pleased to have the opportunity to comment on the Securities and Exchange Commission’s (SEC or Commission) proposed roadmap to implement a global set of financial accounting standards.
October 27 2008
On behalf of its members, the Biotechnology Industry Organization (“BIO”) is pleased to provide comments on the proposed rulemaking, SEC Release No. 34-58572, by the Securities and Exchange Commission (“SEC” or “Commission”) to address excessive market fluctuations of security prices exacerbated by market manipulation, including abusive naked short selling and false rumors. As a result of this market manipulation, the securities prices of many small biotechnology companies have been substantially driven down, harming overall investor confidence in biotechnology companies. Specifically, diminished investor confidence adversely impairs the liquidity and ultimately the viability of emerging biotechnology companies.
October 27 2008
BIO commends the SEC on implementation of the new 10b-21 naked short selling anti-fraud rule and the "Hard T+3 Close Out Requirement" proposal.
Want to learn more about the biotech industry?
Business Solutions Sponsor
